Product Program year 2021 Source: CMS Open Payments

Iclusig

Drug Hematologyoncology

NDC 76189-534-30

Open in the dashboard

General payments

$19,553

7 payments

Research payments

$0

0 payments

Through program year 2021, $19,553 in general payments and $0 in research payments were reported against Iclusig (Hematologyoncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2021 General $15,853 5
2020 General $3,700 2

Breakdown

Who paid General payments · program years 2020–2021
  1. Otsuka Pharmaceutical Co., Ltd. $19,553 7 payments
Top recipients General payments · program year 2021
  1. Koji Sasaki Hematology & Oncology · Houston, TX $8,853 56% · 2 payments
  2. Jorge Cortes-Franco Hematology & Oncology · Houston, TX $5,000 32% · 2 payments
  3. Shin Mineishi Medical Oncology · Hershey, PA $2,000 13% · 1 payment

Each share is of general payments naming this product in 2021.

Specialties paid General payments · program year 2021
  1. Hematology & Oncology Internal Medicine $13,853 87% · 2 practitioners
  2. Medical Oncology Internal Medicine $2,000 13% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2021
  1. Texas $13,853 87% · 2 recipients
  2. Pennsylvania $2,000 13% · 1 recipient

Each share is of general payments naming this product in 2021 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

4,095

Prescriptions dispensed, refills included

Drug cost

$84,883,356

Paid at the pharmacy, in all

Prescribers

248

With 11 or more claims of it

Medicare Part D drugs matched to ICLUSIG, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Iclusig Ponatinib Hcl Same name 248 4,095 $84,883,356

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Yehuda Deutsch Hematology-Oncology FL 62 $1,301,326 None on record
Wendy Stock Hematology-Oncology IL 55 $1,104,104 None on record
Marc Schwartz Hematology-Oncology CO 51 $1,046,850 None on record
Roxie Kneen Nurse Practitioner CA 40 $794,501 None on record
Megan Manuel Nurse Practitioner NC 37 $732,447 $125

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
7 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record